Studies demonstrate Labcorp Plasma Detect MRD Technology can inform treatment strategies and advance cancer research BURLINGTON, N.C., Nov. 19, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced Labcorp Plasma Detect, a tumor-informed, blood-based assay used to detect molecular residual disease (MRD) from circulating tumor DNA (ctDNA), was...Read more
Cardiac Ablation Solutions growth of 71% on strength of pulsed field ablation (PFA) portfolio; Raising FY26 revenue and EPS guidance GALWAY, Ireland, Nov. 18, 2025 /CNW/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its second quarter (Q2) of fiscal year 2026 (FY26), which ended October 24, 2025. Q2 Key Highlights Revenue of $9.0 billion, increased 6.6% as reported...Read more
RANKLIN LAKES, N.J., Nov. 17, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the Conformité Européenne (CE) Marked BD Onclarity™ HPV Assay for the BD COR™ System and the BD Viper™ LT System have been accepted for the World Health Organization (WHO) list of prequalified in vitro diagnostic products, further expanding access to high-quality cervical...Read more
ROSA® Knee with OptimiZe™ Offers Personalized Surgical Planning and Drives Confidence in Delivering Accurate and Reproducible Outcomes1 WARSAW, Ind., Nov. 14, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of ROSA® Knee with OptimiZe™, an enhanced version of its ROSA® Knee System that...Read more
Study shows that rare variants captured by Illumina WGS with DRAGEN™ variant calling explain most of the "missing heritability" in complex human diseases and traits, including those related to blood pressure and cholesterol Results demonstrate the advantages of WGS over WES and genotyping arrays for assessing genetic risk and identifying drug target candidates. SAN DIEGO, Nov. 12, 2025 /PRNewswire/ -- A study published today in...Read more
First-of-its-kind, automated system delivers increased sensitivity, specific identification of disease markers and improved laboratory workflow to support fast, confident diagnoses WALTHAM, Mass. / Nov 12, 2025 / Business Wire / Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced 510(k) clearance of the EXENT® Analyser and Immunoglobulin Isotypes (GAM) Assay**, a first-of-its-kind automated...Read more
FRANKLIN LAKES, N.J., Nov. 12, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, introduces the PureWick™ Portable Collection System, a discreet, first-of-its-kind, battery-powered personal urine management device designed for wheelchair users to help improve mobility around and outside the home. The PureWick™ Portable Collection System builds on the success of the...Read more
Third-quarter 2025 sales of $2.6 billion, up 6% on a reported basis, or up 5% constant currency1 (cc), versus third-quarter 2024 Third-quarter 2025 diluted EPS of $0.48; core diluted EPS2 of $0.79 Generated $1.6 billion cash from operations and $1.2 billion free cash flow3 in the first nine months of 2025. Also returned $550 million to shareholders Full-year 2025 guidance maintained Ad Hoc Announcement Pursuant to Art. 53 LR GENEVA...Read more
Following global commercial launch in September, Illumina Protein Prep's "out of the box" solution drives extraordinary accessibility to proteomics for researchers, with over 40,000 samples processed Sydney Mass Spectrometry is the first facility in the wider Asia Pacific region to offer Illumina Protein Prep, adding to a growing list of institutions revealing biological insights with exceptional clarity at scale Recent...Read more
Q4 revenue of $5.9 billion increased 8.3% as reported, 7.0% FXN and 3.9% organic Q4 GAAP and adjusted diluted EPS grew to $1.72 and $3.96, respectively FY25 revenue of $21.8 billion increased 8.2% as reported, 7.7% adjusted FXN and 2.9% organic FY25 GAAP EPS of $5.82 decreased 0.7%; adjusted diluted EPS of $14.40 grew 9.6% FY25 GAAP and adjusted gross margin up 20 basis points and 140 basis points, respectively, driven by BD...Read more
Raises Full Year Revenue and Margin Guidance ACTON, Mass. / Nov 06, 2025 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its financial results for the three months ended September 30, 2025. Third Quarter Financial Highlights: Revenue of $706.3 million, increased 29.9%, or 28.2% in constant...Read more
SAN DIEGO, Nov. 5, 2025 /PRNewswire/ -- The Chinese Ministry of Commerce (MOFCOM) today announced it will lift the export ban on Illumina, Inc. (NASDAQ: ILMN), which had been in place since March 4, 2025. While the ban will be lifted on November 10, Illumina remains on the Unreliable Entities List (UEL), requiring government approval for instrument purchases. Illumina remains focused on achieving a positive resolution regarding its...Read more
Total revenue from continuing operations increased 10%; constant currency organic revenue grew 9% As reported EPS from continuing operations increased to $1.94; adjusted EPS increased to $2.47 Fiscal 2026 constant currency organic revenue, EPS and free cash flow outlook increased DUBLIN, IRELAND , Nov. 05, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal...Read more
Third quarter net sales of $2.001 billion increased 9.7% on a reported basis, 8.6% on a constant currency1 basis and 5.0% on an organic constant currency1 basis Third quarter diluted earnings per share were $1.16; adjusted1 diluted earnings per share were $1.90, an increase of 9.2% For full-year 2025, Company maintains reported revenue growth guidance, reflecting the latest currency expectations, and narrows constant currency1 and...Read more
FRANKLIN LAKES, N.J., Nov. 4, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced full enrollment of the iliac artery patient cohort in its pivotal AGILITY Investigational Device Exemption (IDE) study, a prospective, multi-center study evaluating the Revello™ Vascular Covered Stent in patients with peripheral arterial disease (PAD). The announcement was made in...Read more
FRANKLIN LAKES, N.J., Nov. 3, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance and Conformité Européenne (CE) marking in the European Union for its Enteric Bacterial Panel* (EBP) and Enteric Bacterial Panel plus* (EBP plus) for the BD COR™ System. By leveraging advanced...Read more
IRVINE, Calif. / Oct 30, 2025 / Business Wire / Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2025. Recent Highlights Q3 sales grew 14.7% to $1.55 billion, or 12.6% adjusted1, with strength across all product groups Q3 TAVR sales grew 12.4%; constant currency1 sales grew 10.6% Q3 TMTT sales of $145.2 million, growth driven by PASCAL and EVOQUE Q3 EPS of $0.502; adjusted1 EPS of...Read more
Revenue of $1.08 billion for Q3 2025, flat compared to Q3 2024 on both a reported and constant currency basis GAAP operating margin of 21.0% and non-GAAP operating margin of 24.5% for Q3 2025 GAAP diluted EPS of $0.98 and non-GAAP diluted EPS of $1.34 for Q3 2025 Cash provided by operations of $284 million and free cash flow of $253 million for Q3 2025 Repurchased 1.2 million shares of our common stock for $120 million at an average...Read more
Portage, Michigan, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the third quarter of 2025: Third Quarter Results Reported net sales increased 10.3% to $6.1 billion Organic net sales increased 9.5% Reported operating income margin of 18.7% Adjusted operating income margin(1) increased 90 bps to 25.6% Reported EPS increased 2.8% to $2.22 Adjusted EPS(1) increased 11.1% to...Read more
Revenue increased by 9% to $1.3 billion; up 8% on a constant currency basis Gross margin up 290 bps to 61.5%; non-GAAP gross margin up 280 bps to 62.0% Income from operations increased 15%; non-GAAP income from operations up 19% Diluted earnings per share of $2.37; non-GAAP diluted earnings per share of $2.55 Operating cash flow of $457 million Note: A webcast of Resmed’s conference call will be...Read more
SAN DIEGO / Oct 30, 2025 / Business Wire / DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights: Revenue grew 22% year-over-year to $1.209 billion on a reported basis and 20% year-over-year on an organic1 basis. U.S. revenue grew 21% and international revenue grew 22% on a reported basis and 18% on an organic1 basis, all on a...Read more
Third-quarter sales from continuing operations of $2.84 billion increased 5% on a reported basis and 2% on an operational basis1,2 Third-quarter U.S. GAAP3 diluted earnings per share (EPS) (loss) from continuing operations of ($0.10); adjusted diluted EPS from continuing operations of $0.69 Andrew Hider joined the company as president and chief executive officer (CEO), now leading the company’s focus to drive continuous improvement and...Read more
Revenue increased 22% to $64 billion GAAP1 operating earnings increased 18% to $668 million; GAAP diluted EPS increased 11% to $1.88 Non-GAAP operating earnings increased 37% to $857 million, driven by segment profit growth across all five of the company's operating segments; non-GAAP diluted EPS increased 36% to $2.55 Cardinal Health raises fiscal year 2026 non-GAAP EPS guidance2 to $9.65 to $9.85 and fiscal year 2026 non-GAAP...Read more
Expected to be immediately accretive to Adjusted Earnings Per Share (EPS)¹ after close Attractive return profile given high growth and strong margin profile of Clario, and meaningful synergies - reflecting the company’s disciplined approach to capital deployment Further strengthens Thermo Fisher’s position as the trusted partner to pharma and biotech customers, delivering important customer benefits WALTHAM, Mass. / Oct 29, 2025 /...Read more
Symplicity blood pressure procedure is now covered for qualifying Medicare patients GALWAY, Ireland, Oct. 28, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the Centers for Medicare & Medicaid Services (CMS) has released the final National Coverage Determination (NCD) on renal denervation, applicable to the Symplicity Spyral™ renal denervation (RDN) system, also...Read more
Prioritized Regulatory Review Process in the U.S. Follows Japan PMDA Approval in September WARSAW, Ind., Oct. 28, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the company's first-to-world iodine-treated total hip replacement system. This is the first product in...Read more
Revenue of $4,100 million, up 5.2 percent year-over-year GAAP Net Income of $331 million, Adjusted EBITDA of $949 million GAAP Diluted Earnings per Share of $1.93, Adjusted Diluted Earnings per Share of $3.00 R&D Solutions quarterly bookings of $2.6 billion, representing a book-to-bill ratio of 1.15x R&D Solutions contracted backlog of $32.4 billion, up 4.1 percent year-over-year Operating Cash Flow of $908 million; Free Cash...Read more
Updates Full-Year Guidance Financial results from Operations for third quarter 2025 versus third quarter 2024: Revenue: $3.56 billion versus $3.28 billion Diluted EPS: $3.12 versus $2.00 Adjusted EPS: $4.18 versus $3.50 Updated Full-Year Enterprise Revenue, Adjusted EPS and Free Cash Flow guidance: Revenue guidance of 7.4% to 8.0%; midpoint lowered 40 bps due to currency and acquisition timing Adjusted EPS range of $16.15...Read more
SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling outcomes equivalent to surgery at seven years SAN FRANCISCO / Oct 27, 2025 / Business Wire / Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data, which showed superior clinical outcomes at one year, also demonstrate excellent long-term valve...Read more
EXTON, Pa., Oct. 27, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced the launch of its West Synchrony™ Prefillable Syringe (PFS) System at CPHI Worldwide in Frankfurt, Germany. This innovative system marks a significant shift in drug delivery solutions by offering a fully verified platform from a single supplier that...Read more
Long-term data shows significant and sustained blood pressure reductions in both office-based and 24-hour ambulatory blood pressure, reinforcing the durability, safety and effectiveness of the Symplicity™ blood pressure procedure in patients prescribed antihypertensive medications GALWAY, Ireland, Oct. 26, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced new, long-term results...Read more
Labcorp plans to make Roche's Elecsys® pTau181 test available nationwide by early 2026 BURLINGTON, N.C., Oct. 23, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer the Elecsys pTau181 test, the only blood test cleared by the U.S. Food and Drug Administration (FDA) to aid in the initial assessment for Alzheimer's disease and other causes of...Read more
Delivered solid growth across Proprietary Products and Contract Manufacturing Segments Achieved double-digit growth in HVP Components Strengthened executive leadership team, including recently appointed CFO Robert McMahon Increases Full-Year 2025 Revenue and EPS Guidance EXTON, Pa., Oct. 23, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative,...Read more
Highlights Quarter three revenue was $2,042.8 million representing an increase of 1.3% on quarter two 2025. Net income for the quarter was $2.4 million or $0.03 per diluted share. Quarter three adjusted EBITDA was $396.7 million or 19.4% of revenue, representing an increase of 0.2% on quarter two 2025. Quarter three adjusted net income was $258.8 million or $3.31 per diluted ordinary share. Gross business wins in the...Read more
FRANKLIN LAKES, N.J., Oct. 22, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a new self-collection solution for HPV testing in markets outside the United States. This new innovation simplifies at-home sample collection for patients and further automates lab processing using high-tech robotics with the BD COR™ System. The new swab technology has been...Read more
MARLBOROUGH, Mass., Oct. 22, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.065 billion during the third quarter of 2025, growing 20.3 percent on a reported basis, 19.4 percent on an operational1 basis and 15.3 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $755 million or...Read more
WALTHAM, Mass. / Oct 22, 2025 / Business Wire / Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the third quarter ended September 27, 2025. Third Quarter Highlights Third quarter revenue grew 5% to $11.12 billion. Third quarter GAAP diluted earnings per share (EPS) was $4.27, in-line with the prior-year quarter. Third quarter adjusted EPS grew 10% to $5.79. ...Read more
SUNNYVALE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended September 30, 2025. Q3 Highlights Worldwide procedures (da Vinci and Ion combined) grew approximately 20% compared with the third quarter of 2024. Da Vinci procedures grew approximately...Read more
WASHINGTON, Oct. 21, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended September 26, 2025. Key Third Quarter 2025 Results Net earnings were $908 million, or $1.27 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $1.89. Revenues increased 4.5% year-over-year to $6.1 billion and non-GAAP core revenue increased 3.0%...Read more
FRANKLIN LAKES, N.J., Oct. 20, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a global leader in medical technology, introduces the BD Incada™ Connected Care Platform, a new scalable, AI-enabled, cloud-based platform that unifies BD device data into one intelligent ecosystem for the first time. The BD Incada™ Platform is available now with the launch of the next-generation BD Pyxis™ Pro Automated Medication...Read more
Acquisition to expand the neuromodulation offerings for people living with chronic pain MARLBOROUGH, Mass., Oct. 17, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Nalu Medical, Inc., a privately held medical technology company focused on developing and commercializing innovative and minimally invasive solutions for patients with chronic...Read more
WALTHAM, Mass. / Oct 16, 2025 / Business Wire / Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced plans to further increase the impact of Thermo Fisher’s proven growth strategy through the use of artificial intelligence (AI) with OpenAI. This collaboration will help to improve the speed and success of drug development, enabling customers to get medicines to patients faster and more cost...Read more
At ASHG, an early access customer from the London Health Sciences Center Research Institute will demonstrate the power of the 5-base genome for accelerating resolution of rare disease cases Proprietary 5-base chemistry and novel DRAGEN algorithms enable dual-omic inquiry, providing researchers with new tool for precision medicine breakthroughs SAN DIEGO, Oct. 15, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced...Read more
Third-quarter reported sales growth of 6.9 percent; organic sales growth of 5.5 percent or 7.5 percent excluding COVID-19 testing-related sales1 Third-quarter GAAP diluted EPS of $0.94; adjusted diluted EPS of $1.30 Reported operating margin of 18.1 percent of sales; adjusted operating margin of 23.0 percent, which reflects a 40 basis point increase ABBOTT PARK, Ill., Oct. 15, 2025 /PRNewswire/ -- Abbott (NYSE: ABT)...Read more
FRANKLIN LAKES, N.J., Oct. 9, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the enrollment of the first patient in the XTRACT™ Registry, a prospective, multi-center, single-arm, post-market registry study designed to evaluate the real-world performance of the Rotarex™ Catheter System in the treatment of patients with peripheral artery disease (PAD)...Read more
FDA-cleared software release enhances navigation and broadens access to advanced imaging for lung biopsy procedures SUNNYVALE, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced that the U.S. Food & Drug Administration (FDA) has cleared software advancements for the Ion endoluminal system...Read more
Gorilla® Pilon Fusion Plating System Introduced for Complex Ankle Fusions Phantom® TTC Trauma Nail Enhances Treatment Options for Complex Hindfoot Injuries WARSAW, Ind., Oct. 8, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, and Paragon 28, a wholly owned subsidiary, today announced the full commercial launch of two innovative solutions for complex foot and ankle...Read more
First procedures completed and enrollment underway in Embrace Gynecology study, furthering the company's progress to expand minimally invasive treatment options to patients in the United States GALWAY, Ireland, Oct. 8, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT) today announced the start of the Embrace Gynecology investigational device exemption (IDE) U.S. clinical study to evaluate the safety and effectiveness...Read more
FRANKLIN LAKES, N.J., Oct. 8, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Opentrons Labworks, Inc., recognized worldwide for accessible lab automation with more than 10,000 robotic systems deployed, today announced a multi-year collaboration. Together, BD and Opentrons will integrate robotic liquid-handling capabilities into BD single-cell multiomics instruments,...Read more
Transaction creates the broadest, most flexible portfolio of orthopedic robotics and navigation technologies, including pathway towards the first fully autonomous robotic technology for orthopedic procedures WARSAW, Ind., Oct. 7, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) ("Zimmer Biomet"), a global medical technology leader, today announced it has completed the acquisition of Monogram...Read more
New business focuses on developing data assets, software, and AI to fuel life science breakthroughs Expands pharma access to large omics datasets to advance target discovery and drug development SAN DIEGO, Oct. 1, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the launch of BioInsight, a new business within Illumina, developed to meet industry demand for deeper biologic insights driven by the need of...Read more
Labcorp to leverage Roche's digital pathology technology to expand access, enhance efficiency and support AI integration across anatomic pathology services BURLINGTON, N.C., Sept. 30, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today a collaboration with Roche to implement the company's FDA-cleared VENTANA® DP 600 and DP 200 slide scanners. The investment...Read more
GALWAY, Ireland, Sept. 29, 2025 /PRNewswire/ -- Medtronic plc (the "Company") (NYSE: MDT) announced today that its wholly-owned indirect subsidiary, Medtronic, Inc., has closed a registered public offering (the "Offering") of €750,000,000 principal amount of 2.950% senior notes due 2030 and €750,000,000 principal amount of 4.200% senior notes due 2045 (collectively, the "Notes"). All of Medtronic, Inc.'s obligations under the Notes are...Read more
More than 800,000 Canadians1 live with peripheral artery disease (PAD) with limited treatment options to date1 The first-of-its-kind dissolvable stent, the Esprit™ BTK Everolimus Eluting Resorbable Scaffold, dissolves over time after it has opened blocked arteries below-the-knee (BTK) The dissolving stent offers the possibility of better outcomes for people with the most severe form of PAD TORONTO, Sept. 29, 2025 /CNW/ --...Read more
Helping Biopharma Labs Reach New Heights in Analytical Performance SANTA CLARA, Calif. / Sep 29, 2025 / Business Wire / Agilent Technologies Inc. (NYSE: A) today announced the release of a new range of high performance liquid chromatography (HPLC) columns ideally suited for biotherapeutics applications. The Agilent Altura Ultra Inert HPLC Columns set a new standard in liquid chromatography performance, providing the reliability and...Read more
HIRC award reinforces Baxter’s industry leadership in preparing for and responding to supply chain disruptions Recognition builds on the HIRC Transparency Badge earned by Baxter in 2023 and 2024, demonstrating continuous commitment to resilient healthcare delivery DEERFIELD, Ill. / Sep 26, 2025 / Business Wire / Baxter International Inc. (NYSE:BAX), a leading global medtech company, today announced that it has been awarded a Gold...Read more
iTaperloc® Complete and iG7™ Hip System with Iodine Technology inhibits bacterial adhesion and prevents biofilm formation on the implant surface to help address the issue of Periprosthetic Joint Infection after total joint replacement WARSAW, Ind., Sept. 25, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the Pharmaceutical and Medical Devices Agency...Read more
Illumina and pharma partners will develop companion diagnostics for historically important KRAS biomarker SAN DIEGO, Sept. 23, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) will partner with multiple global pharmaceutical companies to develop companion diagnostics (CDx) enabled on the TruSight™ Oncology (TSO) Comprehensive genomic profiling test. The continued expansion of tumor-agnostic CDx claims underscores...Read more
FRANKLIN LAKES, N.J., Sept. 22, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a pharmacy automation partnership with Henry Ford Health to develop the health system pharmacy of the future, with an initial focus on a robotic solution that will enable patients to pick up select prescriptions at their convenience — 24 hours a day, seven days a...Read more
The Implantable Tibial Neuromodulation (ITNM) device will expand treatment options for the 16 million people living with urinary urges and involuntary leaks GALWAY, Ireland, Sept. 19, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced today that it has received U.S. Food and Drug Administration (FDA) approval for the Altaviva™ device. The minimally invasive implantable tibial...Read more
Designed for optimized workflows to support earlier detection of patient deterioration Future-ready device features customizable configurations and upgrade capabilities Connects to Baxter’s cloud-based platform DeviceBridge, helping to enable quick, secure transfer of vital signs data to electronic medical records DEERFIELD, Ill. / Sep 16, 2025 / Business Wire / Baxter International Inc. (NYSE:BAX), a leading global medtech company,...Read more
DUBLIN, Ohio, Sept. 15, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today is showcasing its newly operational Consumer Health Logistics Center, a 350,000-square-foot facility in Groveport, Ohio. Purpose-built as a centralized replenishment hub, this facility serves as a vital link in the company's supply chain, efficiently distributing over-the-counter medications, treatments, and diagnostic solutions to a network of more than...Read more
Study to evaluate whether a new approach to pacing the heart can improve the lives of patients with heart failure with preserved ejection fraction (HFpEF) who have limited treatment options today GALWAY, Ireland, Sept. 15, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the initiation of a pivotal study evaluating the use of elevated and personalized cardiac pacing rates for...Read more
New Force Gauge, In-Console Video Replay, and Network CCM features designed for enhanced efficiency SUNNYVALE, Calif., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Intuitive (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced the first in a series of new software capabilities for da Vinci 5, designed to enhance surgeon and hospital efficiency through the delivery of...Read more
Beckman Coulter Also Announces Development of Aß-42 Research Use Only Immunoassay Test BREA, Calif., Sept. 10, 2025 /PRNewswire/ -- Beckman Coulter Diagnostics, a Danaher company and a leader in global clinical diagnostics innovation, today launched the industry's first fully automated Brain-derived Tau (BD-Tau) research use only (RUO) immunoassay test. Access BD-Tau, along with Beckman Coulter Diagnostics' expanding portfolio...Read more
RESEARCH TRIANGLE PARK, N.C. / Sep 10, 2025 / Business Wire / IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced the launch of its Clinical Trial Financial Suite (CTFS), an AI-enabled platform orchestrating all financial aspects of clinical trials. CTFS is designed to eliminate inefficiencies created by...Read more
First-ever investigational device exemption clinical study for robotic-assisted hernia repair in the U.S. presented at the American Hernia Society annual meeting GALWAY, Ireland and NASHVILLE, Tenn., Sept. 4, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT) today announced results from the Enable Hernia Repair clinical study evaluating the performance of the Hugo™ robotic-assisted surgery (RAS) system in inguinal and ventral...Read more
DUBLIN / Sep 04, 2025 / Business Wire / ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today announced that Dr. Steve Cutler has informed the Board of his decision to retire as Chief Executive Officer and the Board has appointed Mr. Barry Balfe, ICON’s Chief Operating Officer, to succeed Dr. Cutler as Chief Executive Officer effective 1 October 2025. Mr. Balfe has also been appointed to the Board. Dr. Cutler will...Read more
Illumina Protein Prep can measure 9500 unique human protein targets, offering new insights into protein biology to fuel novel discovery for treatment of disease Following early access program, customers commend scale, high consistency, and easy sample to insights workflow Launch follows Illumina's announcement of agreement to acquire SomaLogic SAN DIEGO, Sept. 3, 2025 /CNW/ -- Illumina Inc. (NASDAQ: ILMN) today announced...Read more
GALWAY, Ireland, Sept. 2, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced two U.S. Food and Drug Administration (FDA) regulatory milestones that broaden the MiniMed™ 780G system portfolio: clearance of the SmartGuard™ algorithm as an interoperable automated glycemic controller (iAGC), enabling integration with the Instinct sensor, made by Abbott, for type 1 diabetes, and approval...Read more
SANTA CLARA, Calif. / Sep 02, 2025 / Business Wire / Agilent Technologies Inc. (NYSE: A) today announced that its MMR IHC Panel pharmDx (Dako Omnis) has received class C companion diagnostic (CDx) certification under EU in vitro diagnostic regulation (IVDR)1 as a CDx test for colorectal cancer. MMR IHC Panel pharmDx (Dako Omnis) is indicated as an aid to identify mismatch repair (MMR) deficient CRC patients eligible for treatment with...Read more
Navitor is now approved as a minimally invasive alternative to surgery for patients in Europe with symptomatic, severe aortic stenosis (a common and life-threatening heart valve disease) who are at low or intermediate surgical risk CE Mark is based on safety and effectiveness data from the VANTAGE trial presented at the European Society of Cardiology (ESC) Congress 2025 and simultaneously published in JACC: Cardiovascular...Read more
RESEARCH TRIANGLE PARK, N.C. and CAMBRIDGE, Mass., Aug. 28, 2025 /PRNewswire/ -- IQVIA (NYSE: IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, and Flagship Pioneering, the bioplatform innovation company, today announced a strategic collaboration to accelerate the development of breakthrough life sciences companies. The collaboration will help the Flagship ecosystem of...Read more
Agilent delivers strong revenue growth, raises growth outlook Highlights Revenue of $1.74 billion for the third quarter ended July 31, 2025, exceeding revenue guidance and representing growth of 10.1% reported and up 6.1% on a core(1) basis compared with the third quarter of 2024. GAAP net income of $336 million; earnings per share (EPS) of $1.18, up 22% from the third quarter of 2024. Non-GAAP(2) net income of $390 million; EPS...Read more
Published in The Lancet Respiratory Medicine, research reveals sharp rise in OSA, especially among women, highlighting the need for earlier diagnosis, preventative strategies, and personalized care SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced the publication of a landmark study in The Lancet...Read more
SANTA CLARA, Calif. / Aug 20, 2025 / Business Wire / Agilent Technologies Inc. (NYSE: A) today announced that its MMR IHC Panel pharmDx (Dako Omnis) has received FDA approval as a companion diagnostic (CDx) test for colorectal cancer. This test aids in identifying mismatch repair deficient (dMMR) colorectal cancer (CRC) patients who are eligible for treatment with Bristol Myers Squibb’s Opdivo® (nivolumab) alone or Opdivo (nivolumab) in...Read more
Second-quarter 2025 sales of $2.6 billion, up 4% on a reported basis, or up 3% constant currency1 (cc), versus second-quarter 2024 Second-quarter 2025 diluted EPS of $0.35; core diluted EPS2 of $0.76 Generated $889 million cash from operations and $681 million free cash flow3 in the first half of 2025. Also returned $287 million to shareholders Recently launched Tryptyr, a first-in-class treatment for dry eye disease, in the...Read more
11th quarter in a row of mid-single digit organic revenue growth; Poised to accelerate growth GALWAY, Ireland, Aug. 19, 2025 /CNW/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its first quarter (Q1) of fiscal year 2026 (FY26), which ended July 25, 2025. Key Highlights Revenue of $8.6 billion, adjusted revenue of $8.5 billion, increased 8.4% as reported and 4.8%...Read more
Lumipulse® pTau-217/Beta Amyloid 42 Ratio now available nationwide through Labcorp BURLINGTON, N.C., Aug. 18, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the availability of the Lumipulse® pTau-217/Beta Amyloid 42 Ratio, the first blood-based in-vitro diagnostic (IVD) test cleared by the U.S. Food and Drug Administration (FDA) to aid in the diagnosis of...Read more
Fourth quarter revenue was relatively flat at $60.2 billion; revenue increased 21% excluding the impact of a previously communicated contract expiration Fourth quarter GAAP1 operating earnings were $428 million and GAAP diluted EPS was $1.00 Fourth quarter non-GAAP operating earnings increased 19% to $719 million and non-GAAP diluted EPS increased 13% to $2.08 Fiscal Year 2025 adjusted free cash flow was $2.5 billion Fiscal year...Read more
Adds over 750 providers to Cardinal Health's multi-specialty MSO platform, The Specialty Alliance Joins with recent urology acquisitions to bolster The Specialty Alliance's leadership in the urology therapeutic area Cardinal Health MSO platforms reach ~3,000 providers in 32 states upon transaction close DUBLIN, Ohio, Aug. 12, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today announced that The Specialty Alliance, its...Read more
Raising Full Year Revenue and Adjusted Operating Margin Guidance ACTON, Mass. / Aug 07, 2025 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended June 30, 2025. Second Quarter Financial Highlights: Revenue of $649.1 million, up 32.9%, or 31.3% in constant...Read more
Second quarter net sales of $2.077 billion increased 7.0% on a reported basis, 5.4% on a constant currency1 basis and 2.8% on an organic constant currency1 basis Second quarter diluted earnings per share were $0.77; adjusted1 diluted earnings per share were $2.07, an increase of 3.0% Company tightens full-year 2025 reported, constant currency1 and organic constant currency1 revenue growth guidance to 6.7% - 7.7%, 6.2% - 7.2% and 3.5%...Read more
Revenue of $5.5 billion increased 10.4% as reported, 8.5% adjusted FXN and 3.0% organic GAAP and adjusted diluted EPS grew to $2.00 and $3.68, respectively GAAP and adjusted gross margin up 160 basis points and 50 basis points, respectively, driven by BD Excellence GAAP and adjusted operating income up 46.6% and 11.3%, respectively Company raises full-year adjusted diluted EPS guidance to $14.30 to $14.45, reflecting an $0.18...Read more
Total revenue from continuing operations increased 9%; constant currency organic revenue grew 8% As reported EPS from continuing operations increased to $1.79; adjusted EPS increased to $2.34 Fiscal 2026 revenue and free cash flow outlook updated DUBLIN, IRELAND, Aug. 06, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2026 first quarter ended June 30,...Read more
STAAR Surgical is a leader in refractive surgery using Implantable Collamer Lenses, offering solutions for moderate to high myopes Acquisition of STAAR is complementary to Alcon’s laser vision correction business and is expected to be accretive in year two Alcon to purchase all outstanding shares of STAAR for $28 per share in cash, valuing STAAR at approximately $1.5 billion in equity value Ad Hoc Announcement Pursuant to Art. 53...Read more
SANTA CLARA, Calif. / Aug 04, 2025 / Business Wire / Agilent Technologies Inc. (NYSE: A) today announced the introduction of its Dako Omnis family of instruments with three new models—Agilent Dako Omnis 110, 165, and 165 Duo—designed to meet the evolving needs of pathology laboratories of all sizes. These new instruments provide labs with the flexibility to tailor their staining solutions according to volume, workflow, and diagnostic...Read more
FRANKLIN LAKES, N.J., Aug. 4, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced plans to invest more than $35 million and add approximately 50 new jobs to expand prefilled flush syringe manufacturing at its Columbus, Neb. facility to increase the resiliency of the U.S. health care system. The investments will support new BD®...Read more
Revenue of $1.06 billion for Q2 2025, down 3% from Q2 2024 on both a reported and constant currency basis GAAP operating margin of 20.2% and non-GAAP operating margin of 23.8% for Q2 2025 GAAP diluted EPS of $1.49 and non-GAAP diluted EPS of $1.19 for Q2 2025 Cash provided by operations of $234 million and free cash flow of $204 million for Q2 2025 For fiscal year 2025, we now expect: Total company constant currency revenue...Read more
Portage, Michigan, July 31, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the second quarter of 2025: Second Quarter Results Reported net sales increased 11.1% to $6.0 billion Organic net sales increased 10.2% Reported operating income margin of 18.5% Adjusted operating income margin(1) increased 110 bps to 25.7% Reported EPS increased 7.0% to $2.29 Adjusted EPS(1) increased 11.4% to...Read more
| Company | Change | Last Trade |
|---|---|---|
| Mettler-Toledo | 52.94 3.78 | $1,452.35 |
| Insulet | 18.28 5.84 | $331.17 |
| Thermo Fisher Scientific | 14.74 2.57 | $587.48 |
| West Pharmaceutical | 13.30 5.16 | $271.07 |
| Intuitive | 9.38 1.70 | $561.61 |
| Stryker | 7.79 2.16 | $368.27 |
| IQVIA | 7.79 3.59 | $224.90 |
| ResMed | 6.83 2.80 | $250.75 |
| ICON | 6.44 4.07 | $164.56 |
| STERIS | 6.31 2.46 | $263.29 |
| Agilent Technologies | 6.19 4.27 | $151.25 |
| Illumina | 5.50 4.61 | $124.76 |
| Danaher | 5.21 2.34 | $227.39 |
| Labcorp | 4.17 1.59 | $265.64 |
| Abbott | 4.14 3.34 | $128.11 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
